LIPO-C is a compounding-pharmacy-prepared injectable formulation of metabolic cofactors — methionine, choline, L-carnitine, and pantothenic-acid derivatives — marketed as a lipotropic ("fat-mobilising") injection for body-composition contexts. Unlike most compounds in this catalogue, LIPO-C is not a single chemical entity but a fixed-ratio cofactor blend prepared by 503A compounding pharmacies. Its regulatory category differs substantively from FDA-approved injectable pharmaceuticals and from peptide research compounds. This monograph lays out the composition, the rationale for the cofactor blend, the published evidence base, and the regulatory considerations.
Composition.
The most commonly cited LIPO-C composition is the Empower Pharmacy formula: methionine 15 mg/mL, choline chloride 50 mg/mL, L-carnitine 50 mg/mL, dexpanthenol (vitamin B5) 5 mg/mL in sterile aqueous solution. Compositions vary between compounding pharmacies; some include vitamin B12 (methylcobalamin or cyanocobalamin) and/or vitamins B1 and B5. There is no single standardized LIPO-C formula — the exact composition depends on the compounding source.
Mechanism of action.
LIPO-C is a cofactor blend rather than a single-receptor pharmacology, and its mechanistic rationale derives from the biochemistry of each component. Methionine participates in one-carbon metabolism and methylation reactions, including the synthesis of phosphatidylcholine. Choline is the precursor of phosphatidylcholine and is required for hepatic VLDL assembly and lipid export. L-Carnitine mediates mitochondrial transport of long-chain fatty acids for β-oxidation (see L-Carnitine monograph). Dexpanthenol is the alcohol form of pantothenic acid (B5), a precursor of CoA. The combined rationale is that the blend supplies cofactors for hepatic lipid export and mitochondrial fatty-acid oxidation simultaneously.
Research applications and the evidence base.
Published controlled clinical trials of the specific LIPO-C composition for the marketed weight-loss indication are essentially absent. The component-level evidence for each ingredient as a single agent is much stronger — L-carnitine for carnitine-deficiency syndromes (FDA-approved), methionine and choline for hepatic-lipid biology — but extrapolating component evidence to a combined lipotropic-injection effect on body composition is not supported by published Phase III trial data. Compounding pharmacies marketing LIPO-C are operating under 503A authority for individual-patient prescriptions, not under FDA approval for a defined clinical indication.
No human clinical trial has established administration parameters for LIPO-C; VialTalk does not provide community-sourced dosing.
Research context.
LIPO-C occupies a regulatory and clinical category of its own — a 503A-compounded cofactor blend marketed for a cosmetic body-composition outcome that does not appear in any FDA-approved indication for the component agents. Researchers studying lipotropic-cofactor pharmacology should work with the individual components (L-carnitine, choline, methionine) at defined concentrations rather than the blend, where compositional variability between compounding sources confounds interpretation.
Storage and handling.
Compounded LIPO-C solutions should be stored per the compounding-pharmacy package insert — typically refrigerated (2–8 °C) and protected from light. Beyond-use-date varies by compounder; the 503A regulation requires specific BUDs for each formulation.
Quality and COA considerations.
A meaningful COA for a LIPO-C preparation should report identity and concentration for each component, sterility, endotoxin, and a BUD assignment grounded in stability data. Because compositions vary across compounders, a single "LIPO-C" label without a per-component breakdown is effectively unverified. Researchers should treat the specific compounder + formulation as the relevant identity rather than the generic brand name.
Research-use note: This monograph is an educational summary of the composition and biochemistry of LIPO-C. The blend is prepared under 503A compounding-pharmacy authority for individual-patient prescriptions; the marketed weight-loss indication is not FDA-approved as a Phase III clinical claim. Nothing here is medical advice or a usage recommendation.
